The effects of probiotics on gut dysfunction in postinfective irritable bowel syndrome are unknown. We tested whether probiotics influence persistent muscle hypercontractility in mice after recovery from infection with Trichinella spiralis and analyzed the underlying mechanisms. Methods: Mice were gavaged with Lactobacillus paracasei, Lactobacillus johnsonii, Bifidobacterium longum, or Bifidobacterium lactis in spent culture medium from days 10 to 21 after infection. Additional mice received heat-inactivated Lactobacillus paracasei, Lactobacillus paracasei-free spent culture medium, or heat-inactivated Lactobacillus paracasei-free spent culture medium. Lactobacilli enumeration, immunohistochemistry, and cytokine detection (enzyme-linked immunosorbent assay) were performed. Mice were also treated with Lactobacillus paracasei or Lactobacillus paracasei-free spent culture medium from days 18 to 28 after infection. Contractility was measured on days 21 and 28 after infection. Results: Lactobacillus paracasei, but not Lactobacillus johnsonii, Bifidobacterium lactis, or Bifidobacterium longum, attenuated muscle hypercontractility. This was associated with a reduction in the Trichinella spiralis-associated T-helper 2 response and a reduction in transforming growth factor-␤1, cyclooxygenase-2, and prostaglandin E 2 levels in muscle. Attenuation of muscle hypercontractility by Lactobacillus paracasei-free spent culture medium was abolished after heat treatment. Improvement of muscle hypercontractility at day 28 after infection was also observed after the administration of Lactobacillus paracasei or Lactobacillus paracasei-free spent culture medium from day 18 after infection. Conclusions: Probiotics show strain-dependent attenuation of muscle hypercontractility in an animal model of postinfective irritable bowel syndrome. This likely occurs via both a modulation of the immunologic response to infection and a direct effect of Lactobacillus paracasei or a heat-labile metabolite on postinfective muscle hypercontractility. Lactobacillus paracasei may be useful in the treatment of postinfective irritable bowel syndrome.
Background & Aims:
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I
t is generally accepted that symptoms of irritable bowel syndrome (IBS) originate from gut dysfunction that includes altered motility and sensory perception. IBS may occur in 7%-30% of patients recovering from bacterial gastroenteritis, [1] [2] [3] [4] [5] and acute bacterial gastroenteritis is the strongest recognized environmental risk factor for the development of IBS. 6 Patients with postinfective IBS (PI-IBS) have a profile of sensorimotor dysfunction similar to that seen in IBS patients. 7 Patients with PI-IBS show increased intestinal permeability and increased numbers of lymphocytes in rectal biopsy samples. 8 These observations, taken in conjunction with animal studies, 9 suggest that immune activation maintains gut dysfunction in the PI state. Because acute gastroenteritis has been shown to disrupt intestinal microbiota, 10, 11 it is possible that shifts in commensal bacterial populations may contribute to PI gut dysfunction, either directly by modulating neuromuscular excitability 12 or indirectly via the immune system. [13] [14] [15] It follows that correction of gut dysfunction by manipulating commensal microbiota offers therapeutic potential in PI-IBS. There have been no published trials of probiotics in PI-IBS; the role of probiotics in IBS thus remains inconclusive. 16, 17 Previous work from our laboratory has shown that Trichinella spiralis infection in NIH Swiss mice produces changes in excitatory neurotransmission and increased contractility of muscle. These abnormalities persist after recovery of infection, thus generating a model of PI gut dysfunction. In this model, the altered postinflammation physiology is initiated by the T-helper 2 (Th2) cytokine response to the infection and is maintained subsequently by cyclooxygenase (COX)-2 and transforming growth factor (TGF)-␤ production in the neuromuscular layers of the gut. 9, 18 Thus, modulation of the immune response and its consequences may attenuate the development of the persistent alteration in gut physiology.
This study examines the hypothesis that specific strains of probiotic bacteria, administered after an acute intestinal infection, normalize gut neuromuscular dysfunction that persists for 21 to 42 days after infection with T. spiralis in mice. Our results show that Lactobacillus paracasei, but not other tested probiotics, attenuates muscle hypercontractility in this model. Modulation of the underlying immunologic response and mediator generation in the muscularis externa is probably not the sole mechanism for improvement of PI muscle hypercontractility by probiotics. Administration of L. paracasei on days 10 to 21 after infection attenuated muscle hypercontractility by influencing the immune response to infection. A direct effect is also suggested because normalization of PI muscle hypercontractility was also observed when L. paracasei was administered from day 18 after infection, at a time when no discernible mucosal inflammation was observed in the intestine. The effects are strain specific and are seen with spent culture medium (SCM): this suggests that they are mediated by metabolites of bacteria.
Materials and Methods

Bacterial Strains and Culture Conditions
L. johnsonii NCC533, L. paracasei NCC2461, Bifidobacterium longum NCC2705, and B. lactis NCC362 were obtained from the Nestlé Culture Collection (Lausanne, Switzerland) and grown under anaerobic conditions in DE Man-RogosaSharpe (MRS) broth (bifidobacteria with 0.5% cysteine). After 48 hours at 37°C, the number of bacteria was estimated by measuring the optical density at 600 nm (1 OD600 ϭ 10 8 bacteria per milliliter). Bacterial cells were pelleted by centrifugation for 15 minutes at 5000g at 4°C, further resuspended at a concentration of 10 10 /mL in their SCM, and kept in frozen aliquots until use. L. paracasei in SCM was heat-inactivated by autoclaving (heat-inactivated L. paracasei). The SCM was filtered through 0.2 mol/L to obtain bacteria-free SCM (L. paracasei-free SCM).
Animals
Female NIH Swiss mice (6 -8 weeks old) were purchased from the National Cancer Institute (Bethesda, MD) and kept under specific pathogen-free conditions at McMaster University central animal care facilities. All experiments were approved by the McMaster University Animal Care Committee and the Canadian Council on Animal Care.
Trichinella spiralis Infection and Worm Counts
T. spiralis parasites were obtained from the department of zoology at the University of Toronto, and the colony was maintained through serial infections alternating between male Sprague-Dawley rats and male CD1 mice. The larvae were obtained from infected rodents after infection by using a modification 19 of the technique described by Castro and Fairbairn. 20 Infections were performed by gavage of 375 T. spiralis larvae per mouse. To examine the effect of probiotics on the PI state, probiotics were administered on day 10 after infection. To ensure that the infection had cleared, we performed worm counts in 3 mice per group before the start of probiotic administration (day 10 after infection) and at days 12 and 14 after infection. The intestine was removed, opened longitudinally, rinsed, and placed in Hanks' balanced salt solution for 3 hours at 37°C. Recovered adult worms were counted under a dissecting microscope.
Probiotic Administration
To determine whether probiotic bacteria influence persistent muscular dysfunction, T. spiralis-infected mice were gavaged daily from day 10 to 21 after infection with 100 L of MRS as control or with 100 L of 10 10 L. paracasei, L. johnsonii, B. longum, or B. lactis per milliliter of SCM. To investigate whether the presence of live bacteria is necessary for the effect on PI muscular dysfunction, additional T. spiralis-infected mice were gavaged from day 10 to 21 after infection with 100 L of MRS, 10 10 
To assess the effect of this bacterium on contractility in naive mice, uninfected mice were gavaged with either L. paracasei or MRS at the time points similar to those used in infected mice. To examine whether the effect of probiotics on postinfection muscle hypercontractility required administration during active intestinal inflammation, T. spiralis-infected mice were also gavaged from day 18 to 28 after infection with MRS, L. paracasei, or L. paracasei-free SCM. Mice were killed at days 14, 21, and 28 after infection.
Intestinal Microbiota Counts
Ileal and colonic segments (2 cm) were obtained under sterile conditions. Contents were pooled with 1 mL of 0.9% NaCl/10% glycerol used to wash the lumen. Tissues were ground in 2 mL of 0.9% NaCL/10% glycerol by using a Polytron (Kinematica AG, Switzerland). Samples were stored at Ϫ70°C until analysis. On plating on semiselective media, 21 bacterial populations were estimated by counting the colony-forming units. Lactobacilli, bifidobacteria, and bacteroides were incubated anaerobically (AnaeroGen; Oxoid, Basingstoke, UK) at 37°C for 48 hours. Enterobacteria and enterococci were incubated aerobically at 37°C for 24 hours. Bacterial counts were expressed in log 10 colonyforming units per gram of feces or tissue. The presence of L. paracasei NCC2461 was monitored by random amplified polymorphic DNA fingerprinting 22, 23 with the 2 following oligonucleotides: GGTTGGGTGAGAATTGCACG and CGGCCAGCTGGTCAGCC (Microsynth, Balgach, Switzerland).
Muscle Contractility
In vitro muscle contractility was measured as described previously 24 at days 21 and 28 after infection. Briefly, jejunal strips suspended in muscle bath containing oxygenated Krebs solution at 37°C were stretched by tension equivalent to 0.5 g, and contractility of the intestinal segment was recorded after a 40-minute equilibration period by force transducers (FT03C; Grass, Quincy, MA) connected to a polygraph (model 7D; Grass). Data were stored in a computer by using dedicated software (Acquire 5.0; Alfred Bayatti) and were analyzed offline with Grafview 4.1 (Alfred Bayatti).
In experiments designed to select probiotic bacteria on the basis of their effect on the PI muscle dysfunction, contractility was assessed by using a dose response to carbachol (10 Ϫ8 to 10 Ϫ5 mol/L). Dose response to carbachol was also used to investigate the effect of late administration of probiotics (day 18 after infection) on PI hypercontractility.
In experiments conducted to investigate the effect of L. paracasei, L. paracasei-free SCM, or heat-inactivated L. paracasei on PI dysfunction, contractility was assessed by electrical field stimulation (EFS) at nerve (50 V, 10 Hz, 0.5 ms) parameters or pharmacologically by 10 Ϫ6 mol/L carbachol, 10 Ϫ5 mol/L 5-hydroxytryptamine, or 50 mmol/L KCl.
At the end of the experiments, the length and weight of each tissue were recorded to correct for cross-sectional area, as described previously. 24 The force exerted by the muscle strips was expressed in milligrams per square millimeter. Area under the curve (AUC) was calculated for 1 minute before and 1 minute after stimulation. Tonic contraction was defined as the difference between mean tone before and after stimulation. Maximal tension was defined as the difference between the maximal amplitude of contraction after stimulation and the mean amplitude of phasic contractions before stimulation.
Longitudinal Myenteric Muscle Preparation
For analysis of protein within the longitudinal muscle layer, the entire jejunum was dissected, rinsed in ice-cold sterile phosphate-buffered saline, and cut into 4 sections. The mesentery was carefully removed, and the pieces of intestine were mounted onto a glass rod. The muscle layer was carefully scraped off with a clean cotton swab, snap-frozen, and stored at Ϫ70°C until analysis. Successful isolation of muscle was confirmed by histological evaluation. Muscle tissue was placed in 1 mL of lysis buffer containing 10% NP-40, 10 mg/mL phenylmethylsulfonyl fluoride in isopropanol, 1 mg/mL aprotinin, and 1 mg/mL leupeptin. After the tissue was homogenized, the total protein concentration was measured (Bio-Rad protein assay, Hercules, CA), and samples were aliquoted and stored at Ϫ70°C for enzyme-linked immunosorbent assay (ELISA) determinations.
Enzyme-Linked Immunosorbent Assay
Interleukin (IL)-4 and IL-13 were measured in a longitudinal myenteric muscle preparation (LMMP) obtained 14 days after infection with commercial kits (Quantikine M Murine, Minneapolis, MN) by following the manufacturer's directions. TGF-␤1 and prostaglandin E 2 (PGE 2 ) were also measured in LMMP obtained 21 days after infection (Quantikine M Murine).
To activate latent TGF-␤1 to immunoreactive TGF-␤1 detectable by the assay, samples were assayed after acidification with 2.5N acetic acid and 10 mol/L urea and neutralization with 2.7 mol/L NaOH/1 mol/L HEPES. Results from ELISA determinations were adjusted to the protein concentration of the sample and expressed as picograms per milliliter per milligram of total protein.
Immunohistochemistry
COX-2 detection was performed on paraffin blocks of mouse jejunum obtained 21 days after infection and processed as previously described. 25 The antibody used to identify COX-2 was a specific rabbit polyclonal affinity-purified antibody directed against amino acids 584 -598 of the murine COX-2 (Cayman Chemical, Ann Arbor, MI). Negative controls were performed by omitting the primary antibody and by blocking antibody/protein complex formation for COX-2. For the latter, a COX-2 murine blocking peptide (Cayman Chemical) was incubated with the primary antibody before its application on the slides.
Tissue sections were analyzed with light microscopy (Leica DM/LS; Mikroskopie & Systeme GmbH, Wetzlar, Germany), and quantification of immunostaining was performed on a computer with dedicated software (NIH Image 1.62).
RANTES Messenger RNA Expression
Total RNA was isolated from 1-cm jejunal segments 21 days after infection by using TriPure Isolation reagent (Roche Diagnostic AG, Rotkreuz, Switzerland) according to the manufacturer's instructions. Residual DNA was eliminated with the NucleoSpin RNA II kit (Macherey-Nagel, Oensingen, Switzerland). RNA quantification was performed with the Ribogreen RNA kit (Molecular Probes, Juro AG, Lucerne, Switzerland). RNA quality was controlled by using the RNA 6000 Nano Labchip kit in an Agilent 2100 bioanalyzer (Agilent Technologies SA, Basel, Switzerland), as described in the Reagent Kit Guide. Gene-expression analysis was performed with the murine DNA chips MG-U74Av2 (Affymetrix, High Wycombe, England) as previously described, 26 except that data analysis was performed with the global error assessment method. 27 Quantitative analysis of RANTES (regulated upon activation, normal T cells expressed and secreted) was performed by real-time polymerase chain reaction (PCR). Reverse transcription of total RNA (2 g) was performed by using oligo (dT15) as primer and avian myeloblastosis virus reverse transcriptase according to the manufacturer's protocol (Catalysis AG, Basel, Switzerland). Realtime PCR was performed in triplicate according to the Applied Biosystems (Foster City, CA) protocol with the GeneAmp 5700 Sequence Detection System. Data were analyzed with Sequence Detector software (Applied Biosystems). According to the comparative threshold cycle (Ct) method, 28 the average Ct values for RANTES were normalized with respect to the average Ct values of the housekeeping gene hypoxanthine guanine phosphoribosyl transferase to yield the ⌬Ct. The average ⌬Ct value obtained from the uninfected mice group was then subtracted from the average ⌬Ct value for each other group to give the ⌬⌬Ct (-fold change). The RANTES gene primer (forward, GGAGTATTTCTACAC-CAGCAGCAA; reverse, CACTTGGCGGTTCCTTCGA)/TaqMan probe (6-carboxy fluorecein-CTTGCAGTCGTGTTTGTC) combination was designed and synthesized by Applied Biosystems (Assays-by-Design) on sequence from the National Center for Biotechnology Information public database specific for the mouse RANTES gene (AF 065947). The hypoxanthine guanine phosphoribosyl transferase primers/TaqMan probe combination was designed and synthesized by Applied Biosystems (Assays-onDemand; Mm00446968_m1).
Statistical Analysis
Data are presented as mean Ϯ SD. Medians and interquartile ranges (IQR) were used for worm count experiments (n ϭ 3 per group; nonparametric distribution). Statistical testing was performed by analysis of variance and global error assessment analysis of variance. 27 
Results
Effect of Probiotic Strains on Worm Expulsion
None of the tested probiotic strains interfered with parasite eviction. Consistent with previous findings, 24 worm expulsion was complete by day 14 after infection, and no worms were recovered after day 14 in any group that had previously been infected with T. spiralis and treated with probiotics or MRS. Similarly, when probiotics were administered on day 10 after infection, no significant effect was seen in the number of worms recovered at later time points. Median worm recovery on day 10 after infection was 2 (IQR, 9.5) in T. spiralis-MRS, 6.5 (IQR, 4) in L. paracasei-treated animals, and 7 (IQR, 12) in L. paracasei-free SCM-treated mice (all not significant). On day 12 after infection, worm recovery was 0.5 (IQR, 1) in T. spiralis-MRS, 0 (IQR, 2.5) in L. paracasei-treated animals, and 1 (IQR, 3) in L. paracasei-free SCM-treated mice (all not significant). On day 14 after infection, no worms were recovered in any group of mice previously infected with T. spiralis.
Effect of Probiotics on Postinfective Hypercontractility Is Strain Specific
To investigate whether the administration of probiotic bacteria influences PI hypercontractility, T. spiralis-infected mice were given unfermented MRS as control or the probiotics 10 10 L. paracasei, L. johnsonii, B. longum, or B. lactis per milliliter of SCM from day 10 to day 21 after T. spiralis infection. Contractility of whole-muscle strips showed that uninfected mice and T. spiralis-infected mice that had received L. paracasei displayed significantly lower maximal tension than MRS-treated mice ( Figure 1A ; Table 1 ). Attenuation of PI hypercontractility was evident after stimulation with carbachol 10 Ϫ7 mol/L (P ϭ 0.008), 10 Ϫ6 mol/L (P ϭ 0.01), and 10 Ϫ5 mol/L (P ϭ 0.05). B. lactis decreased maximal tension only after stimulation with 10 Ϫ7 mol/L carbachol (P ϭ 0.01). B. longum and L. johnsonii tended to have lower maximal tension after stimulation with 10 Ϫ7 mol/L carbachol, but this did not achieve statistical significance. L. paracasei and, to a lesser extent, B. lactis tended to decrease the AUC after 10 Ϫ5 mol/L carbachol stimulation when compared with MRS-treated mice (P ϭ 0.06 and P ϭ 0.1, respectively; Figure 1B ; Table 1 ).
Lactobacillus paracasei Activity on Postinfective Hypercontractility Is Present in Lactobacillus paracasei-Free Spent Culture Medium and Is Heat Labile
Groups of T. spiralis-infected mice were given, from day 10 to day 21 after infection, live L. paracasei in their SCM, heat-inactivated L. paracasei in their SCM, or L. paracasei-free SCM. To test whether the administration of L. paracasei could affect contractility in naive mice, uninfected mice were initially divided in 2 groups that received MRS alone or live L. paracasei in SCM from day 10 to day 21 after infection. Measurements were identical in the 2 groups, indicating that L. paracasei had no effect on contractility in naive mice (data not shown). Because no differences in contractility were observed and to increase the n value in controls, results from these 2 groups were pooled into a single group of controls. After pharmacological and nonpharmacological stimulation of contraction, all uninfected mice had significantly lower contractility when compared with mice 21 days after T. spiralis infection treated with MRS (P Ͻ 0.01; Figure 2 ; Table 2 ).
To examine whether changes in neural function are associated with the L. paracasei effect on PI hypercontractility, we examined differences in muscle contraction in response to EFS of intramural nerves. In T. spiralisinfected mice, tonic contraction after EFS decreased significantly in L. paracasei and L. paracasei-free SCMtreated groups when compared with MRS-treated mice (P ϭ 0.04 and P ϭ 0.02, respectively; Figure 2A ). The AUC was not calculated after EFS because of the short duration of stimulation (20 minutes).
Carbachol stimulation of contractions paralleled these results. The AUC was decreased in L. paracasei (P ϭ 0.04) and in L. paracasei-free SCM-treated mice (P ϭ 0.04) when compared with MRS-treated mice ( Figure  2B ). Maximal tension, shown in Table 2 , was significantly decreased in L. paracasei-free SCM-treated mice when compared with MRS-treated mice (P ϭ 0.03).
To investigate whether the changes in muscle contractility were dependent on the muscarinic receptor, contractions were also stimulated with 5-hydroxytryptamine and KCl. After simulation with 5-hydroxytryptamine, L.
paracasei-free SCM-treated mice had lower maximal tension (P ϭ 0.04) and AUC (P ϭ 0.01) when compared with MRS-treated mice. Finally, after KCl stimulation, maximal tension was lower in L. paracasei-treated mice when compared with MRS-treated mice (P ϭ 0.03). The AUC was also significantly decreased in L. paracasei and L. paracasei-free SCM-treated mice when compared with MRS-treated mice (P ϭ 0.04 and P ϭ 0.02, respectively). T. spiralis-infected mice treated with heat-inactivated L. paracasei did not show significant attenuation of PI hypercontractility after any stimulation or in any of the parameters analyzed (Table 2) .
These results, together with the fact that the SCM free of live bacteria is also active, suggested that the inhibitory substance is an L. paracasei heat-labile metabolite produced during fermentation. To further investigate this, we performed muscle contractility experiments by using heat-inactivated L. paracasei-free SCM. As shown in Table 3 , attenuation of muscle hypercontractility after carbachol 10 Ϫ6 mol/L by L. paracasei-free SCM was abolished after heat treatment ( Table 3) .
Administration of Lactobacillus paracasei From Day 18 After Infection Also Attenuates Postinfective Hypercontractility
To investigate whether L. paracasei could attenuate muscle hypercontractility when administered after the inflammatory response to infection had subsided, T. spiralis-infected mice were gavaged from day 18 until day 28 after infection with L. paracasei, L. paracasei-free SCM, or MRS. Uninfected mice received MRS. In vitro contractility was assessed on day 28 after infection. Administration of L. paracasei-free SCM to previously infected mice attenuated maximal tension when compared with mice that had received MRS (P Ͻ 0.05 at carbachol 10 Ϫ6 and 10 Ϫ5 mol/L). The AUC was also reduced (P ϭ 0.03 at carbachol 10 Ϫ6 mol/L; P ϭ 0.09 at carbachol 10 Ϫ5 mol/L). Live L. paracasei decreased maximal tension (P ϭ 0.04 at carbachol 10 Ϫ5 mol/L) and AUC (P ϭ 0.09 at 10 Ϫ5 mol/L; Figure 3 ).
Lactobacillus paracasei-Free Spent Culture Medium Attenuates the Trichinella spiralisInduced T-Helper 2 Response in Longitudinal Myenteric Muscle Preparation 14 Days After Infection
In previous studies, it was determined that the acute T. spiralis-induced Th2 response is transient and normalizes in the PI state. 9 Therefore, we measured protein for IL-4 and IL-13 only in the LMMP obtained 14 days after T. spiralis infection. Figure 4 shows that IL-4 and IL-13 levels in the LMMP of mice 14 days after infection treated with MRS were higher than in uninfected mice (P Ͻ 0.0001 and P Ͻ 0.0001, respectively). In T. spiralis-infected mice, this Th2 response was attenuated in L. paracasei-free SCMtreated mice when compared with MRS-treated mice (IL-4, P Ͻ 0.0001; IL-13, P ϭ 0.01). IL-4, but not IL-13, was decreased in L. paracasei-treated mice when compared with MRS-treated mice (P ϭ 0.002).
Lactobacillus paracasei and Lactobacillus paracasei-Free Spent Culture Medium Attenuate Transforming Growth Factor-␤1 and Prostaglandin E 2 Induced by Trichinella spiralis Infection in Longitudinal Myenteric Muscle Preparation 21 Days After Infection
Previous studies in our laboratory have proposed that it is the increased production of mediators such as TGF-␤1 and PGE 2 in the muscle layer that maintains dysfunction in the T. spiralis PI state. 9,18 Therefore, we measured TGF-␤1 and PGE 2 protein 21 days after infection. Administration of L. paracasei or L. paracasei-free SCM to T. spiralis-infected mice markedly decreased TGF-␤1 and PGE 2 levels in LMMP when compared with MRS-treated mice (P Ͻ 0.01; Figure 5 ). 
Lactobacillus paracasei and Lactobacillus paracasei-Free Spent Culture Medium Attenuate the Cyclooxygenase-2 Expression Induced by Trichinella spiralis Infection in Longitudinal Myenteric Muscle Preparation 21 Days After Infection
Immunohistochemistry was performed to investigate COX-2 protein expression in the intestine. All groups of mice had positive labeling for COX-2 in the mucosa ( Figure 6 ). There was weak COX-2 staining in the muscle of uninfected mice ( Figure 6A ) when compared with T. spiralis-infected mice treated with MRS ( Figure 6B ). T. spiralis-infected mice treated with L. paracasei ( Figure 6C ) or L. paracasei-free SCM ( Figure  6D ) had decreased COX-2 staining in muscle when compared with T. spiralis mice treated with MRS. Specificity of immunostaining was confirmed in blocking experiments by co-incubating peptide COX-2 with the primary antibody ( Figure 6E ). Quantitative analysis of 4 mice per group confirmed a decrease in the percentage of COX-2 labeling per total area in the muscle layer, from a mean of 1.5% (Ϯ1.0%) in T. spiralis-infected mice treated with MRS to 0.24% (Ϯ0.1%) in T. spiralisinfected mice treated with L. paracasei-free SCM (P ϭ 0.05) and to 0.36% (Ϯ0.2%) in mice treated with L. paracasei (P ϭ 0.03). Uninfected mice had a similar percentage per total area compared to T. spiralis-infected mice treated with L. paracasei-free SCM or L. paracasei (0.38% Ϯ 0.2%).
Lactobacillus paracasei and Lactobacillus paracasei-Free Spent Culture Medium Attenuate RANTES Messenger RNA Induced by Trichinella spiralis Infection 21 Days After Infection
Gene-array analysis of total RNA from full-thickness jejunal tissues showed an up-regulation of RANTES messenger RNA (mRNA) expression by T. spiralis infection and a normalization after treatments with L. paracasei and L. paracasei-free SCM. On day 21 after infection, T. spiralis induced a significant increase (1.8-fold) in RANTES mRNA expression level when compared with uninfected mice (P ϭ 0.0007). RANTES mRNA basal levels were completely restored after treatment of T. spiralis-infected mice with L. paracasei and with L. paracasei-free SCM (i.e., there were no significant differences in RANTES mRNA levels between uninfected mice and L. paracasei or L. paracasei-free SCM-treated mice; P ϭ 0.2 and 0.17, respectively). Quantitative real-time PCR confirmed the increase in RANTES mRNA after T. spiralis infection and showed a tendency to normalization after probiotic treatment (Figure 7) . 
Effect of Trichinella spiralis Infection and Lactobacillus paracasei Treatment on Intestinal Microbiota
To determine whether changes in neuromuscular activity may be associated with major changes of the intestinal flora, the numbers of enterobacteria, enterococci, bacteroides, bifidobacteria, and total lactobacilli were assessed in the ileum and the colon of T. spiralisinfected mice given MRS, L. paracasei, or L. paracasei-free SCM and of uninfected mice given MRS alone, from day 10 to day 21 after infection (Table 4) . T. spiralis infection decreased enterococcus counts in the ileum and colon. Enterococcus counts were restored by treatment with L. paracasei, but not by L. paracasei-free SCM. Treatment with L. paracasei decreased bacteroides counts in the colon independently of T. spiralis infection. Parasite infection tended to decrease the number of total lactobacilli in the ileum and colon compared with uninfected mice, but this did not achieve statistical significance. In the animals that received L. paracasei and L. paracasei-free SCM, no significant increase in the total number of lactobacilli was observed, compared with T. spiralis- infected animals that did not receive probiotics. Bifidobacteria were under detection limits in all samples analyzed (Ͻ3.3 log 10 colony-forming units per gram).
L. paracasei was recovered only in the animals that were fed live L. paracasei (ileum, 4.6 Ϯ 1.8; colon, 6.7 Ϯ 0.5 log 10 colony-forming units per gram) and not from mice treated with L. paracasei-free SCM or MRS or from uninfected controls.
Discussion
This study shows the efficacy of L. paracasei in attenuating the persistence of muscle hypercontractility after primary T. spiralis infection in NIH Swiss mice. It is important to note that, under the experimental conditions described, the probiotic did not achieve this effect by influencing the kinetics of worm expulsion. The PI nature of the model was preserved, and the results indicate that the probiotics acted on aspects of the host response.
NIH Swiss mice develop marked and sustained abnormalities in neuromuscular function that last until at least 42 days after infection with T. spiralis. 29 Measurements with full-thickness small-bowel sections have shown hypercontractility of intestinal muscle and impaired acetylcholine release on days 21-42 after infection, long after the infection has resolved. These are accompanied by altered motility assessed in vivo. 30 Changes in muscle contraction are absent after infection in athymic mice and thus require T lymphocytes. Th2 cytokines are transiently increased during acute infection, returning to normal by day 21 after infection, suggesting that Th2 cytokines initiate but do not maintain muscle hypercontractility in this model. 18 There is evidence for a close relationship between intestinal microbiota and gut motility. There are fewer migrating myoelectric complexes in germ-free rats when compared with conventional counterparts. 31 Introduction of conventional flora increased the frequency of myoelectric complexes in the proximal intestine and promoted aboral propagation of activity fronts. 32 Promotion or suppression of the initiation and aboral migration of myoelectric complexes is species dependent. 33 In this study, the L. paracasei effect on PI muscle hypercontractility was not restricted to pharmacological stimulation of contraction with carbachol. These findings indicate that the attenuation of PI hypercontractility is not dependent on the muscarinic receptor. Furthermore, L. paracasei also attenuated hypercontractility after KCl depolarization, suggesting that the effect of the probiotic occurs at a step in excitation/contraction coupling that is independent of agonist receptor occupancy. The effect of components of the gut microbiota in shaping intestinal physiology has been proposed in an elegant study on germ-free mice colonized with Bacteroides thetaiotaomicron. 34 This common gut commensal of mice and humans was found to alter expression of genes, such as L-glutamate transporter, L-glutamate decarboxylase, and vesicleassociated protein-33, that are involved in neurotransmission, and of muscle-specific proteins such as enteric ␥-actin, and cysteine-rich protein-2.
Previous work in our laboratory has shown that muscle hypercontractility in T. spiralis infection has an immunologic basis, because it is markedly attenuated in athymic mice, 35 in mice deficient in STAT6, 34 and in mice in which the immune response had been shifted experimentally to Th1. 35 We observed a decrease of Th2 cytokines in the LMMP on day 14 after infection by L. paracasei and the SCM when administration was performed from day 10 after infection. IFN-␥, as measured by ELISA, was undetectable (data not shown). This suggests that the observed effect on PI hypercontractility could be due, at least in part, to a reduction in Th2 cytokines by L. paracasei or its metabolites released in the SCM. A study comparing the pattern of colonization and immune response by L. paracasei and L. johnsonii has suggested preferential induction of Th1 and Th2 patterns, respec- tively. 38 An earlier in vitro study by the same group showed an initial Th1 stimulation by L. paracasei, followed by an inhibition of both Th1 and Th2 CD4 ϩ cells that resembled anergy. 39 However, it is important to emphasize that our model occurs in the context of a highly polarized Th2 response and that in vitro results may not be directly extrapolated to the in vivo situation. COX-2 is the key enzyme for the production of PGE 2 , which is known to induce longitudinal muscle contraction. 40 -42 TGF-␤ is a multifunctional cytokine with anti-inflammatory properties that can also induce fibrosis in a number of systems and enhance smooth muscle contraction. 43 Previous studies in our laboratory have suggested that Th2 cytokines up-regulate TGF-␤ in the smooth muscle, which is one of the possible mediators maintaining hypercontractility at the PI state. Also, exposure of TGF-␤ to smooth muscle cells increases COX-2 protein expression and PGE 2 production. The mechanisms whereby Th2 cytokines increase COX-2 protein and PGE 2 remain unclear but may involve increased affinity of the muscarinic or eicosanoid receptor or activation of postreceptor signaling pathways at the level of the smooth muscle cell. 44 Our results suggest that L. paracasei, or its metabolites, interferes with this sequence of events, attenuating IL-4 -induced production of TGF-␤, COX-2, and PGE 2 in the muscle layer. This is supported by the demonstration of lower IL-4 protein in the LMMP from L. paracasei or L. paracaseifree SCM-treated mice 14 days after T. spiralis when compared with T. spiralis MRS-treated mice. In keeping with our previous studies, the attenuation of the Th2 response 14 days after infection was accompanied by a significant reduction in TGF-␤1, COX-2, and PGE 2 in the muscle layer at 21 days after infection compared with MRS-treated infected mice. Thus, when administered on day 10 after T. spiralis infection, L. paracasei modulates the immune response to infection and normalizes mediator production and muscle function.
In this study, L. paracasei also attenuated the muscle contraction induced by electrical stimulation at neural parameters. Because macrophages have been implicated in neural, but not muscle, dysfunction in T. spiralis infection, 45 some beneficial effects of L. paracasei could result from modulation of innate immunity. 46 We have recently begun an investigation of the range of transcriptional responses induced by L. paracasei in the host tissues that are not restricted to the muscularis externa. We performed gene-array analysis in whole jejunal tissue obtained 21 days after infection. Gene-expression analysis indicates that L. paracasei and L. paracasei-free SCM administration normalized the expression of RANTES mRNA, a gene involved in innate immune responses, which was up-regulated in T. spiralis-infected mice. In another model, injections of RANTES in rat skin led to up-regulation of prostaglandins. RANTES has also been proposed as a mediator of bronchial hyperresponsiveness in asthma. 47 In our study, down-regulation of RANTES by probiotic treatment could have contributed to the attenuated inflammatory response and reduced PI muscle hypercontractility.
Modulation of the Th2 immune response to infection by L. paracasei or its SCM during the early stages of infection is not necessary for the attenuation of downstream expression of mediators in the muscle layer and of PI hypercontractility. Administration of this probiotic strain from day 18, when Th2 cytokines in the LMMP return to normal and no overt inflammatory infiltrate is observed in the intestine, 29 attenuated hypercontractility as measured on day 28 after infection. In the PI state, mediators such as TGF-␤, COX-2, and PGE 2 are increased in the muscle layer. Our results suggest that L. paracasei can attenuate an established PI dysfunction by down-regulating the local production of mediators that maintain muscle hypercontractility after infection. The precise mechanism underlying this interaction is under investigation. The demonstration of efficacy of L. paracasei when administered at day 18 after infection is of clinical importance because patients are likely to seek treatment only after resolution of acute illness and after the development of chronic symptoms.
It has been shown that the normal intestinal microbiota is remarkably disturbed in patients with acute gastroenteritis. 10, 11 Human studies have suggested that there may be qualitative or quantitative differences in the intestinal microbiota composition of patients with IBS. 48 -51 In this study, T. spiralis infection decreased the total enterococcus counts in the intestine. Treatment with L. paracasei restored enterococcus counts to levels observed in uninfected mice. Although L. paracasei-free SCM normalized intestinal muscle function, it did not restore enterococcus counts. Total lactobacilli tended to be lower in T. spiralis-infected mice, irrespective of treatment administration. Finally, bacteroides counts in the colon were reduced in T. spiralis-infected mice treated with L. paracasei. This suggests that changes in the intestinal microbiota in the PI state may be a consequence of enteric infection and that a direct role in the maintenance of muscle hypercontractility is unlikely. However, we cannot rule out that an altered intestinal microbiota after enteric infection participates in the initiation of muscle dysfunction and that qualitative, rather than quantitative, modulation of flora at this time point with specific probiotic strains or their metabolites prevents the progression to PI-IBS.
The T. spiralis model is similar in many aspects to PI-IBS. Altered gut motility is evident in both models after recovery from the infection. 7, 51 Changes in the mucosal compartment in PI-IBS patients are subtle and include enteroendocrine cell hyperplasia and increased numbers of CD3 ϩ cells. 8 However, it is unclear how such changes might alter the contractility of smooth muscle. We have proposed that changes in muscle contractility are maintained after infection by the production of mediators by resident cells of the muscularis externa. 9 Clinical studies on the effect of probiotics on IBS have yielded controversial results. Dietary administration of L. plantarum 299V has been shown to improve abdominal pain and to normalize stool frequency in constipated patients with IBS, 16 whereas L. rhamnosus GG did not improve pain but had a beneficial effect in diarrhea-predominant IBS patients. 17 To our knowledge, no studies have been performed on the effect of probiotics in patients with PI-IBS. Our results raise the possibility that L. paracasei could be useful in attenuating PI gut dysfunction in humans and in treating PI-IBS.
